GRAIL to Present at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Rhea-AI Summary

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. The company's management will deliver their presentation on Wednesday, September 24, 2025, at 8:00 a.m. ET.

Investors and interested parties can access both the live webcast and replay through GRAIL's investor relations website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.

News Market Reaction

+9.12%

25 alerts

+9.12% News Effect

+7.8% Peak in 26 min

+$121M Valuation Impact

$1.45B Market Cap

0.4x Rel. Volume

On the day this news was published, GRAL gained 9.12%, reflecting a notable positive market reaction. Argus tracked a peak move of +7.8% during that session. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $121M to the company's valuation, bringing the market cap to $1.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

MENLO PARK, Calif., Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2^nd Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m. ET. 

Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-bernstein-insights-healthcare-leaders-and-disruptors--2nd-annual-healthcare-forum-302552726.html

SOURCE GRAIL, Inc.

FAQ

When is GRAIL (GRAL) presenting at the Bernstein Healthcare Forum 2025?

GRAIL will present at the Bernstein Healthcare Forum on Wednesday, September 24, 2025, at 8:00 a.m. ET.

How can investors access GRAIL's Bernstein Healthcare Forum presentation?

Investors can access both the live webcast and replay through GRAIL's investor relations website at investors.grail.com.

How long will GRAIL's Bernstein Healthcare Forum presentation be available for replay?

The webcast will be archived and available for replay for at least 30 days after the event.

What is GRAIL's (GRAL) main business focus?

GRAIL is a healthcare company whose mission is to detect cancer early when it can be cured.